Polaryx Therapeutics Inc. has announced the upcoming launch of the SOTERIA trial, a clinical study to further evaluate PLX-200, an investigational therapy for Krabbe disease and other lysosomal storage disorders (LSDs). The company presented new preclinical data on PLX-200 at the 22nd Annual WORLDSymposium™ on February 6, 2026, in San Diego. The findings demonstrated that orally administered gemfibrozil, the active compound in PLX-200, promoted anti-inflammatory gene expression and reduced neuro-inflammation in a mouse model of Krabbe disease. The SOTERIA trial is expected to begin in the first half of 2026, following a safe-to-proceed letter from the FDA received in October 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651725) on February 10, 2026, and is solely responsible for the information contained therein.